These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
170 related articles for article (PubMed ID: 10674705)
1. Intravitreal administration of antisense oligonucleotides: potential of liposomal delivery. Bochot A; Couvreur P; Fattal E Prog Retin Eye Res; 2000 Mar; 19(2):131-47. PubMed ID: 10674705 [TBL] [Abstract][Full Text] [Related]
2. Intraocular delivery of oligonucleotides. Gomes Dos Santos AL; Bochot A; Fattal E Curr Pharm Biotechnol; 2005 Feb; 6(1):7-15. PubMed ID: 15727552 [TBL] [Abstract][Full Text] [Related]
3. "Smart" delivery of antisense oligonucleotides by anionic pH-sensitive liposomes. Fattal E; Couvreur P; Dubernet C Adv Drug Deliv Rev; 2004 Apr; 56(7):931-46. PubMed ID: 15066753 [TBL] [Abstract][Full Text] [Related]
4. [Potential of liposomes for the intravitreal injection of therapeutic molecules]. Bochot A; Lajavardi L; Camelo S; Bourges JL; Behar-Cohen F; de Kozak Y; Fattal E Ann Pharm Fr; 2011 Mar; 69(2):100-7. PubMed ID: 21440102 [TBL] [Abstract][Full Text] [Related]
5. Intravitreal delivery of oligonucleotides by sterically stabilized liposomes. Bochot A; Fattal E; Boutet V; Deverre JR; Jeanny JC; Chacun H; Couvreur P Invest Ophthalmol Vis Sci; 2002 Jan; 43(1):253-9. PubMed ID: 11773039 [TBL] [Abstract][Full Text] [Related]
6. Ocular delivery of nucleic acids: antisense oligonucleotides, aptamers and siRNA. Fattal E; Bochot A Adv Drug Deliv Rev; 2006 Nov; 58(11):1203-23. PubMed ID: 17097190 [TBL] [Abstract][Full Text] [Related]
7. Characterization of a novel intraocular drug-delivery system using crystalline lipid antiviral prodrugs of ganciclovir and cyclic cidofovir. Cheng L; Hostetler KY; Lee J; Koh HJ; Beadle JR; Bessho K; Toyoguchi M; Aldern K; Bovet JM; Freeman WR Invest Ophthalmol Vis Sci; 2004 Nov; 45(11):4138-44. PubMed ID: 15505067 [TBL] [Abstract][Full Text] [Related]
8. Antiviral activity and ocular kinetics of antisense oligonucleotides designed to inhibit CMV replication. Henry SP; Miner RC; Drew WL; Fitchett J; York-Defalco C; Rapp LM; Levin AA Invest Ophthalmol Vis Sci; 2001 Oct; 42(11):2646-51. PubMed ID: 11581212 [TBL] [Abstract][Full Text] [Related]
9. [The use of liposomes as intravitreal drug delivery system]. Bejjani RA; Jeanny JC; Bochot A; Behar-Cohen F J Fr Ophtalmol; 2003 Nov; 26(9):981-5. PubMed ID: 14631286 [TBL] [Abstract][Full Text] [Related]
10. Liposomes as a drug delivery system for antisense oligonucleotides. Juliano RL; Akhtar S Antisense Res Dev; 1992; 2(2):165-76. PubMed ID: 1392538 [TBL] [Abstract][Full Text] [Related]
11. Intravitreal toxicology and duration of efficacy of a novel antiviral lipid prodrug of ganciclovir in liposome formulation. Cheng L; Hostetler KY; Chaidhawangul S; Gardner MF; Beadle JR; Keefe KS; Bergeron-Lynn G; Severson GM; Soules KA; Mueller AJ; Freeman WR Invest Ophthalmol Vis Sci; 2000 May; 41(6):1523-32. PubMed ID: 10798672 [TBL] [Abstract][Full Text] [Related]
12. Liposomes for intravitreal drug delivery: a state of the art. Bochot A; Fattal E J Control Release; 2012 Jul; 161(2):628-34. PubMed ID: 22289436 [TBL] [Abstract][Full Text] [Related]
13. Treatment of herpes retinitis in an animal model with a sustained delivery antiviral drug, liposomal 1-O-octadecyl-SN-glycerol-3-phosphonoformate. Cheng L; Hostetler KY; Chaidhawangul S; Gardner MF; Ozerdem U; Bergeron-Lynn G; Mach-Hofacre B; Mueller AJ; Severson GM; Freeman WR Retina; 1999; 19(4):325-31. PubMed ID: 10458299 [TBL] [Abstract][Full Text] [Related]
14. The delivery of antisense therapeutics. Akhtar S; Hughes MD; Khan A; Bibby M; Hussain M; Nawaz Q; Double J; Sayyed P Adv Drug Deliv Rev; 2000 Oct; 44(1):3-21. PubMed ID: 11035194 [TBL] [Abstract][Full Text] [Related]
15. Current status of delivery systems to improve target efficacy of oligonucleotides. Shoji Y; Nakashima H Curr Pharm Des; 2004; 10(7):785-96. PubMed ID: 15032703 [TBL] [Abstract][Full Text] [Related]
16. Cationic liposomes improve stability and intracellular delivery of antisense oligonucleotides into CaSki cells. Lappalainen K; Urtti A; Söderling E; Jääskeläinen I; Syrjänen K; Syrjänen S Biochim Biophys Acta; 1994 Dec; 1196(2):201-8. PubMed ID: 7841184 [TBL] [Abstract][Full Text] [Related]
17. Intratracheal versus intravenous liposomal delivery of siRNA, antisense oligonucleotides and anticancer drug. Garbuzenko OB; Saad M; Betigeri S; Zhang M; Vetcher AA; Soldatenkov VA; Reimer DC; Pozharov VP; Minko T Pharm Res; 2009 Feb; 26(2):382-94. PubMed ID: 18958402 [TBL] [Abstract][Full Text] [Related]
18. Intravitreal toxicology in rabbits of two preparations of 1-O-octadecyl-sn-glycerol-3-phosphonoformate, a sustained-delivery anti-CMV drug. Cheng L; Hostetler KY; Gardner MF; Avila CP; Bergeron-Lynn G; Keefe KS; Wiley CA; Freeman WR Invest Ophthalmol Vis Sci; 1999 Jun; 40(7):1487-95. PubMed ID: 10359331 [TBL] [Abstract][Full Text] [Related]
19. In vivo delivery of phosphorothioate oligonucleotides into murine retina. Hangai M; Tanihara H; Honda Y; Kaneda Y Arch Ophthalmol; 1998 Mar; 116(3):342-8. PubMed ID: 9514488 [TBL] [Abstract][Full Text] [Related]
20. Gel and solid matrix systems for the controlled delivery of drug carrier-associated nucleic acids. Fattal E; De Rosa G; Bochot A Int J Pharm; 2004 Jun; 277(1-2):25-30. PubMed ID: 15158966 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]